Featured Stories

Corporate video

100 Years of Innovation

At Daiichi Sankyo we can draw upon our rich legacy. Our experience – more than 100 years of innovation – helps us to deliver promising new medicines to patients as shown in our corporate video. read more...

Life as a family

Building a better future

Daiichi Sankyo helps to build a better future for orphans in Eastern Europe. We support the transformation of a Russian orphanage. Family apartments are to replace large dormitories. Our employees contribute to this initiative and the first children have already moved in. read more...

Featured News

Date Description  
11-14-2014Company Plant Expansion: Daiichi Sankyo Inaugurates New Building for Pharmaceutical Development in Pfaffenhofen, Bavaria PDF
09-01-2014Company Global Survey of Cardiologists Highlights Complexity of Managing Non-Valvular Atrial Fibrillation and Reinforces Need for Individualized Approach to Patient Care PDF
08-25-2014Company ESC Congress 2014: Make Your Heart Feel Good! PDF
05-17-2014Company World Hypertension Day 2014 PDF
04-06-2014Company Combination of Sun Pharma and Ranbaxy in India PDF
03-31-2014Research Daiichi Sankyo Initiates Phase 3 ENSURE-AF Study, Investigating Once-Daily Edoxaban in Patients with Atrial Fibrillation Undergoing Cardioversion PDF
01-09-2014Company Daiichi Sankyo Submits SAVAYSATM (edoxaban) Tablets New Drug Application to the U.S. FDA for Once-Daily Use for Stroke Risk Reduction in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism PDF
01-07-2014Company Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism PDF
12-19-2013Company Launch of LIXIANA® in Japan PDF
07-29-2013Research Daiichi Sankyo expands collaborative drug discovery program to Germany, Switzerland, and Austria
06-27-2013Company Data Reveals Changes in Management of Patients Living with Atrial Fibrillation in Europe PDF
05-21-2013Company Daiichi Sankyo increases sales in FY 2012
04-25-2013Research Perosphere and Daiichi Sankyo Enter into a Clinical Trial Agreement to Evaluate the Efficacy and Safety of PER977 to Reverse the Anticoagulant Activity of the Investigational, Oral, Once-Daily Factor Xa Inhibitor Edoxaban PDF
03-22-2013Company Daiichi Sankyo announces new five-year business plan
03-14-2013Company Daiichi Sankyo Recognized Among the 2013 Rebrand 100 Global Awards Winners PDF
02-27-2013Company Ranbaxy surpasses 2012 guidance
01-31-2013Company Daiichi Sankyo reports higher sales and profit
11-13-2012Company Daiichi Sankyo posted financial results for first six month of financial year 2012
10-25-2012Research Daiichi Sankyo Completes Enrolment in Hokusai – VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE PDF
10-24-2012Research ArQule and Daiichi Sankyo announce discontinuation of Phase 3 MARQUEE clinical Trial in Non-Small Cell Lung Cancer
07-09-2012Company Jan Van Ruymbeke to become new CEO of Daiichi Sankyo Europe PDF
05-11-2012Company Daiichi Sankyo posted results for financial year 2011 PDF
03-06-2012Company Ranbaxy Launches Atorvastatin in Germany PDF
11-07-2011Company Daiichi Sankyo Europe boosts net sales PDF
10-04-2011Company Ranbaxy to extend Daiichi Sankyo product reach to pharmacists across Italy PDF
06-07-2011Company European survey highlights the risk to patients caused by inconsistency in hypertension management PDF
04-22-2011Company First market approval in Japan for LIXIANA(®) (Edoxaban) PDF
04-18-2011Research Global phase III trial with selective c-MET inhibitor tivantinib (ARQ 197) starts enrolling patients PDF
04-18-2011Company Daiichi Sankyo offers assistance to victims of the Great East Japan earthquake PDF
03-14-2011Company Daiichi Sankyo contributes to relief efforts for Japan earthquake victims PDF
02-28-2011Company Plexxikon Inc. To Join Daiichi Sankyo Group PDF
01-12-2011Research Daiichi Sankyo and ArQule enroll first non-small cell lung cancer patient into global phaseIII trial PDF
12-02-2010Company Daiichi Sankyo completes enrollment of the Edoxaban global phase III engage AF-TIMI 48 study PDF
10-29-2010Company Daiichi Sankyo raised its profit forecast by almost 18% PDF
10-29-2010Company AstraZeneca and Daiichi Sankyo announce Co-promotion agreement for Esomeprazole (Nexium) PDF
10-12-2010Research ArQule and Daiichi Sankyo expand drug discovery collaboration in oncology PDF
06-22-2010Company Daiichi Sankyo remains on growth course in Europe PDF
04-06-2010Company Daiichi Sankyo submits first new drug application for oral factor Xa inhibitor edoxaban PDF
03-08-2010Company Daiichi Sankyo launches guide on International Women's Day PDF
02-26-2010Research HOKUSAI VTE - largest single phase III trial for the treatment and prevention of recurrent VTE start PDF
10-20-2009Company Improvement through Movement - new educational programme launched PDF
10-20-2009Research MorphoSys and DAIICHI SANKYO Forge Alliance to Develop Novel Antibody Therapies PDF
09-06-2009Company Substantial increase in sales and employee numbers at DAIICHI SANKYO EUROPE in 2008 PDF
09-01-2009Company Ranbaxy introducing osteoporosis drug EVISTA® into the Romanian market PDF
09-01-2009Research Edoxaban - next generation oral anticoagulant under investigation to help prevent stroke in patients PDF
07-10-2009Company DAIICHI SANKYO and Lilly receive U.S. FDA approval for EFFIENT® PDF
03-11-2009Research DAIICHI SANKYO awarded the "Best Cardiovascular Pipeline" PDF
03-08-2009Company Time for change - International Womens Day PDF
03-02-2009Company DAIICHI SANKYO takes over cardiovascular sales force from Merck Serono in Italy PDF
02-23-2009Company European Commission Approves EFIENT® (prasugrel) PDF
02-02-2009Company DAIICHI SANKYO appoints Managing Director for Ireland PDF
01-22-2009Company Blood pressure goal missed by two thirds of patients PDF